Vaxcyte (PCVX) Net Income towards Common Stockholders (2019 - 2026)

Vaxcyte (PCVX) has reported Net Income towards Common Stockholders for 8 consecutive years, with -$322.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 113.95% year-over-year to -$322.9 million; the TTM figure through Mar 2026 stood at -$1.3 billion (down 160.47% YoY), while the FY2025 annual figure was -$1.4 billion, down 60.03% from the prior year.
• Net Income towards Common Stockholders rose to -$322.9 million in Q1 2026 per PCVX's latest filing, from -$378.2 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $92.7 million in Q3 2023 and bottomed at -$623.7 million in Q4 2023.
• Historically, Net Income towards Common Stockholders has averaged -$188.6 million across 5 years, with a median of -$117.3 million in 2024.
• On a YoY basis, Net Income towards Common Stockholders climbed as much as 259.99% in 2023 and fell as far as 699.14% in 2023.
• Vaxcyte's Net Income towards Common Stockholders stood at -$78.0 million in 2022, then tumbled by 699.14% to -$623.7 million in 2023, then surged by 81.19% to -$117.3 million in 2024, then sank by 222.39% to -$378.2 million in 2025, then advanced by 14.61% to -$322.9 million in 2026.
• Business Quant data shows PCVX's Net Income towards Common Stockholders at -$322.9 million in Q1 2026, -$378.2 million in Q4 2025, and -$331.1 million in Q3 2025.